| Metabolic Dysfunction-Associated Steatohepatitis |
ACTRN12624000039583: Evaluating the effect of Dapagliflozin on Alanine Transaminase Levels in Type 2 Diabetic Patients with Non Alcoholic Fatty Liver Disease |
|
|
| Not yet recruiting | 4 | 192 | | | MTI Lady Reading Hospital, MTI Lady Reading Hospital | Non Alcoholic Steatohepatitis, Type 2 Diabetes Mellitus | | | | |
| Ongoing | 4 | 62 | Europe | Ketanest-S, Solution for infusion, Ketanest-S | Maastricht Universitair Medisch Centrum, Maastricht UMC+ | Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, stable Inflammatory Bowel Disease, Irritable Bowel Syndrome | | | | |
2012-001975-36: Dietary polyunsaturated fatty acids for decreasing lipid hepatic content in children with fatty liver supplementazione di acidi grassi polinsaturi per ridurre l'accumulo di lipidi nel fegato di bambini con steatosi epatica |
|
|
| Ongoing | 4 | 80 | Europe | DHA, NA, Chewable capsule, soft | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA, Dipartimento di Pediatria | Nonalcoholic steatohepatitis Steatoepatite nonalcoolica, fatty liver fegato grasso, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2009-015927-94: Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide? |
|
|
| Ongoing | 4 | 36 | Europe | Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets, Victoza, Metformin 500mg tablets, Glucophage SR 500 mg prolonged release tablets | Hull and East Yorkshire NHS Trust | Polycystic Ovary SyndromeNon-alcoholic Steatohepatitis | | | | |
2011-003010-17`ACTRN12609000224224: Randomized double-blind intervention trial to assess the efficacy of vitamin D3 supplementation vs placebo in reducing hepatic steato-inflammation and cardio-metabolic risk profile in patients affected by type 2 diabetes and non-alcoholic fatty liver disease (NAFLD/NASH) STUDIO D’INTERVENTO RANDOMIZZATO CONTRO PLACEBO PER VALUTARE L’EFFICACIA DELLA SUPPLEMENTAZIONE ORALE CON VITAMINA D3 NEL RIDURRE LA STEATOSI E L\'INFIAMMAZIONE NEL FEGATO E I FATTORI DI RISCHIO CARDIOVASCOLARI IN ADULTI DIABETICI AFFETTI DA STEATOSI/STEATOEPATITE NON ALCOLICA (NAFLD/NASH) |
|
|
| Ongoing | 4 | 100 | Europe | DIBASE*OS GTT 10ML 10000UI/ML, DIBASE*OS GTT 10ML 10000UI/ML | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA, Fondi PRIN 2008 | prevention and reduction of risky alcohol consumption | | | | |
2018-002162-38: A study comparing the effect of Dulaglutide (TRULICITY®) add-on to dietary reinforcement versus dietary reinforcement alone in patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis Une étude comparant l'effet du Dulaglutide (TRULICITY®) en plus du renforcement diététique versus le renforcement diététique seul chez des patients diabétiques de type 2 et porteurs d'une stéatohépatite non alcoolique (NASH). |
|
|
| Not yet recruiting | 4 | 120 | Europe | Solution for injection in pre-filled pen, TRULICITY | CHRU de Nancy, LILLY France | Patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis (NASH). Patients diabétiques de type 2 atteints d'une stéatohépatite non alcoolique (NASH)., Patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis (NASH). Patients diabétiques de type 2 atteints d'une stéatohépatite non alcoolique (NASH)., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-001987-31: Combined Treatment of fatty liver Inflammation and type 2 diabetes Kombinierte Behandlung der Fettleberentzündung und Typ 2 Diabetes |
|
|
| Not yet recruiting | 4 | 142 | Europe | Film-coated tablet, Solution for injection in pre-filled pen, Jardiance, Ozempic | Deutsche Diabetes Forschungsgesellschaft e.V., German Center for Diabetes Research (DZD e.V), Boehringer Ingelheim Pharma GmbH, Novo Nordisk A/S | Diabetes mellitus type 2 (T2D) and non-alcoholic steatohepatitis (NASH) Typ 2 Diabetes und nicht-alkoholische Fettleberentzündung, Type 2 Diabetes and non-alcoholic fatty liver inflammation Typ 2 Diabetes und nicht-alkoholbedingte Fettleberentzündung, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT03950505: To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes |
|
|
| Recruiting | 4 | 60 | RoW | Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks | Yonsei University | Non-alcoholic Steatohepatitis, Type2 Diabetes | 12/20 | 12/20 | | |
ChiCTR1900023611: Efficacy and Safety of Benaglutide on Non-alcoholic Steatohepatitis in T2DM Patients: A Randomised Open Clinical Trial |
|
|
| Recruiting | 4 | 50 | | Benaglutide ;Lifestyle | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shanghai Commission of Science and Technology | Nonalcoholic hepatosteatotis | | | | |
NCT04976283: Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver |
|
|
| Recruiting | 4 | 123 | RoW | Pioglitazone, Zolid, Empagliflozin, Diampa, Pioglitazone + Empagliflozin, Zolid + Diampa | Getz Pharma | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD | 05/23 | 11/23 | | |
| Not yet recruiting | 4 | 93 | Europe | dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring | Central Hospital, Nancy, France, Eli Lilly and Company | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | 09/23 | 03/24 | | |
| Recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
| Recruiting | 4 | 120 | RoW | Lifestyle intervention, Placebo, Berberine | Fudan University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, The Affiliated Hospital of Hangzhou Normal University, Tianjin Third Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Xinjiang Medical University | Non-alcoholic Steatohepatitis | 12/23 | 07/24 | | |
Ertu-NASH, NCT05644717: Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD |
|
|
| Not yet recruiting | 4 | 164 | NA | Ertugliflozin 5 mg, 15mg | Getz Pharma | Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, Tolerance | 03/24 | 03/24 | | |
| Enrolling by invitation | 4 | 140 | Canada | Semaglutide Treatment, Sitagliptin 100mg | University Health Network, Toronto, Novo Nordisk A/S | Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD | 04/24 | 12/24 | | |
NCT06138821: ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial |
|
|
| Not yet recruiting | 4 | 30 | US | ESG, Endoscopic Sleeve Gastroplasty, Endoscopic Suturing, GLP1-RA, Semaglutide | Pichamol Jirapinyo, MD, MPH | Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, NAFLD, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Diseases, Diabetes, Diabetes Mellitus, Type 2, Diabetes Mellitus, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis | 07/25 | 12/25 | | |
ChiCTR2200066073: To evaluate the efficacy and safety of Pien Tze Huang in the treatment of non-alcoholic steatohepatitis (damp heat and phlegm stasis syndrome): a multicenter, randomized, double-blind, placebo-controlled clinical trial |
|
|
| Not yet recruiting | 4 | 144 | | Pien Tze Huang ;Pien Tze Huang placebo | Shuguang Hospital Affiliated with Shanghai University of TCM; Zhangzhou Pien Tze Huang Pharmaceutical Co., LTD, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. | Non-alcoholic steatohepatitis | | | | |
2019-002073-56: A study to investigate the efficacy and safety of Aramchol in patients with a form of fatty liver disease. |
|
|
| Not yet recruiting | 3/4 | 2000 | Europe | Aramchol, Tablet | Galmed Research and Development, Ltd., Galmed Research and Development, Ltd. | Nonalcoholic Steatohepatitis (NASH), NASH is a chronic liver disease caused by the build-up of too much fat in the liver, along with inflammation and liver damage., Diseases [C] - Digestive System Diseases [C06] | | | | |
